Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review
- 1 October 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 157 (4), 649-655
- https://doi.org/10.1111/j.1365-2133.2007.08068.x
Abstract
Experts on psoriasis convened with authorities from other medical specialties to discuss the recently described association between psoriasis, obesity and subsequent cardiovascular comorbidity. Similar to other diseases of increased systemic inflammation, psoriasis has been linked to a heightened risk of myocardial infarction, especially in the more severely affected, younger patients. However, unlike in other inflammatory diseases - such as rheumatoid arthritis - more severely affected patients with psoriasis are much more likely to be obese. Importantly, the pathophysiology of both psoriasis and obesity shows many shared cytokines that are known to contribute to features of the metabolic syndrome, such as hypertension, dyslipidaemia and insulin resistance. The strong association between psoriasis and obesity potentially makes psoriasis an important healthcare issue that requires an update in its standard of care. This meeting reviewed the evidence-based literature and addressed how, moving forward, dermatologists and other specialists may redefine the magnitude of health risk associated with more severe psoriasis and its comorbidities, while clarifying both the epidemiology and pathophysiology of the association with obesity.Keywords
This publication has 49 references indexed in Scilit:
- Obesity and Diabetes in the Developing World — A Growing ChallengeNew England Journal of Medicine, 2007
- Prevalence of cardiovascular risk factors in patients with psoriasisJournal of the American Academy of Dermatology, 2006
- Impact of Obesity and Smoking on Psoriasis Presentation and ManagementArchives of Dermatology, 2005
- Cigarette Smoking, Body Mass Index, and Stressful Life Events as Risk Factors for Psoriasis: Results from an Italian Case–Control StudyJournal of Investigative Dermatology, 2005
- The metabolic syndromeThe Lancet, 2005
- Obesity as the core of the metabolic syndrome and the management of coronary heart diseaseCurrent Medical Research and Opinion, 2004
- A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJournal of the American Academy of Dermatology, 2002
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final ReportCirculation, 2002
- Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialThe Lancet, 2000
- Disease concomitance in psoriasisJournal of the American Academy of Dermatology, 1995